---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015454"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:16:49.133563+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics Q1 net loss widens to $34.8M; cash runway into 2025

## Summary
- Net loss of $34.8M ($0.71 per share) vs. $31.6M ($0.65) in Q1 2022; revenue dropped to $3.8M from $7.7M.
- R&D expense rose to $29.0M (Q1 2022: $26.2M) driven by clinical trial costs for CFT7455, CFT8634, CFT1946.
- Cash, equivalents and marketable securities were $305.0M as of March 31, 2023, expected to fund operations into 2025.
- Phase 1 dose-escalation data for CFT7455 (monotherapy in multiple myeloma) and CFT8634 (synovial sarcoma) expected in H2 2023.
- IND submission for CFT8919 (NSCLC) targeted for H1 2023; first patient dosed in CFT1946 Phase 1/2 trial in January.

## SEC filing metadata
- accession: 0001628280-23-015454
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828023015454/0001628280-23-015454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828023015454/cccc-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015454
- JSON: https://secwatch.observer/filing/0001628280-23-015454.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015454.txt

## Key facts
- Earnings Releases
  C4 Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $3.8 million, net income $34.8 million, EPS $0.71.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $3.8 million
  - Net income: $34.8 million
  - EPS: $0.71
  - Result: reported results
  source text: will participate in the Jefferies Global Healthcare Conference in New York. FIRST QUARTER 2023 FINANCIAL RESULTS Revenue: Total revenue for the first quarter of 2023 was $3.8 million, compared to $7.7 million for the first quarter of 2022. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023015454/0001628280-23-015454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.